Zürich (ots) - Der Verein Campaigning Summit Switzerland erhält den eidgenössischen Ritterschlag ...
Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
Hatfield, England (ots/PRNewswire) - Eisai announced today that 12 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, from 1-5 June 2012.
These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to patients and their families affected by cancer.
"Our human health care mission is to help address unmet medical needs and increase benefits to patients and their families," said Takashi Owa, Ph.D., Chief Scientific Officer, Eisai Product Creation Systems. "Our portfolio of oncology compounds and therapies underscores our commitment to this important mission."
The following Eisai abstracts are accepted for presentation at this year's ASCO meeting:
Product Abstract Name A Phase II Single Arm, Feasibility Study of Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Eribulin Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer (EBC) Abstract No: TPS1145 Poster Session A Phase 1b Dose Escalation Study of Eribulin Mesylate in Combination with Capecitabine in Patients with Eribulin Advanced/Metastatic Cancer Abstract No: 2552 Poster Session Lenvatinib (E7080) Treatment of Refractory Metastatic Renal Cell Carcinoma (RCC) with Lenvatinib (E7080) and Everolimus Abstract No: TPS4682 Poster Session Lenvatinib A Phase IB Study of Lenvatinib (E7080) in Combination (E7080) with Temozolomide for Treatment of Advanced Melanoma Abstract No: 8594 Poster Session Lenvatinib Treatment of Advanced RAI-refractory Differentiated Thyroid Cancer (DTC); Cytokine and Lenvatinib Angiongenic Factor (CAF) Profiling in Combination with Tumour Genetic Analysis to Identify Markers Associated E7080 with Response Abstract No: 5518 Poster Discussion Lenvatinib A Phase II Trial of the Multitargeted Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (E7080) (MTC) Abstract No: 5591 Poster Session A Phase I Dose-Finding Study of of Golvatinib (E7050) a cMET and Eph Receptor Targeted Multi-Kinase Inhibitor, Administered Orally QD to Patients with Advanced Solid E7050 Tumours Abstract No: 3030 Poster Discussion A Phase I Dose-Finding Study of Golvatinib (E7050), a c-Met and EPH Receptor Targeted Multi-Kinase Inhibitor Administered Orally BID to Patients with Advanced Solid E7050 Tumours Abstract No: 3079 Poster Session Phase I Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Patients with Farletuzumab Platinum-Sensitive Epithelial Ovarian Cancer (EOC) MORAb-003 Abstract No: 5062 Poster Session Phase I and Pharmacokinetic Study of Farletuzumab in Farletuzumab Solid Tumours MORAb-003 Abstract No: 3084 Poster Session Amatuximab, A Chimeric Monoclonal Antibody to Amatuximab Mesothelin, in Combination with Pemetrexed and Cisplatin in Patients with Unresectable Pleural Mesothelioma MORAb-009 Results of a Multicentre Phase II Clinical Trial Abstract No: 7030 Poster Discussion A First-in-Human Phase I Study of MORAb-004 (M4), a Humanised Monoclonal Antibody Recognising Endosialin MORAb-004 (TEM-1), in Patients with Solid Tumours Abstract No: 3016 Poster Discussion
Notes to Editors
Eisai in Oncology
Eisai is dedicated to discovering, developing and producing innovative oncology therapies that can make a difference and impact the lives of patients and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives for better understanding of the needs of patients and their families to increase the benefits health care provides. Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.
Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the treatment of patients with breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease and whose prior therapy should have included an anthracycline and a taxane. Eribulin belongs to a class of antineoplastic agents, the halichondrins, which are natural products, isolated from the marine sponge Halichondria okadai. It is believed to work by inhibiting the growth phase of microtubule dynamics without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases (RTKs), including KDR (VEGFR-2), Flt-1 (VEGFR-1), FGFR1, PDGFR-beta and c-kit involved in angiogenesis and tumour proliferation.[2,3]
It is currently being investigated as a treatment for thyroid, hepatocellular, endometrial and other solid tumour types.
Farletuzumab is an investigational, humanized IgG1 monoclonal antibody targeting folate receptor alpha which is over-expressed on a number of epithelial-derived cancers, but largely absent in normal tissue. It is currently being developed as a potential treatment for ovarian and lung cancers. Significantly, farletuzumab has received orphan drug designation for ovarian cancer in the US, EU and Switzerland.
MORAb-004 is an investigational humanized IgG1 monoclonal antibody that recognizes a cell surface protein, endosialin, also called Tumour Endothelial Marker-1 (TEM1) and CD248, which is expressed on tumour associated pericytes, tumour stromal cells and directly on a subset of malignant cells. Pericytes are specialised cells that support the formation of blood vessels that support blood to tumours for their growth and survival. Expression of endosialin in tumours has been observed by several independent laboratories and experiments, and blocking endosialin function has been shown to inhibit tumour growth and metastasis. MORAb-004 is currently being investigated as a monoclonal antibody for its potential treatment of many types of cancer. An Investigational New Drug <http://www.morphotek.com/pipeline/Definitions-(1).aspx> application was opened for MORAb-004 in 2009. MORAb-004 has received US FDA orphan drug designation <http://www.morphotek.com/pipeline/Definitions-(1).aspx> for sarcoma.
Amatuximab (MORAb-009) is an investigational chimeric IgG1 antibody that targets a cell surface glycoprotein, mesothelin, which is over-expressed on a number of cancers. Mesothelin is thought to be involved in cell adhesion. Its presence is associated with a range of cancers, including pancreatic ductal adenocarcinoma, mesothelioma, epithelial ovarian cancer, and lung adenocarcinoma. Researchers at the National Cancer Institute (NCI) and the Johns Hopkins University have independently validated mesothelin as a potential target of immuno-based therapies. Amatuximab is currently being investigated clinically as a monoclonal antibody for its potential treatment of mesothelioma.
Eisai is one of the world's leading R&D-based pharmaceutical companies and has defined its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc). Eisai recently expanded their UK Hatfield facility which now supports the company's growing European, Middle Eastern and African (EMEA) business.
Eisai concentrates its R&D activities in three key areas:
- Neuroscience, including: Alzheimer's disease, multiple sclerosis, neuropathic pain, epilepsy, depression - Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc and supportive cancer therapies; pain relief, nausea - Vascular/Immunological reaction including: acute coronary syndrome, atherothrombotic disease, rheumatoid arthritis, psoriasis, Crohn's disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, and Belgium.
For further information please visit our web site http://www.eisai.com
Morphotek(R), Inc., a subsidiary of Eisai, is a biopharmaceutical company specialising in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.
For more information, please visit http://www.morphotek.com.
1. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011; 377: 914 -923.
2. Matsui J et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumour MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14: 5459-65.
3. Matsui J et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumour activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008; 122: 664-71.
Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / Cressida
Robson, +44(0)7947-231513 / +44(0)790-831-4155,
/ , email@example.com ; Tonic Life Communications:
/ Leah Peyton, +44(0)207-798-9262 / +44(0)7788-191434,
firstname.lastname@example.org / email@example.com